Menomune

Menomune

(men′ŏ-mūn″)
A freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis.
References in periodicals archive ?
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/meningococcal-vaccines-market/
Although neither meningococcal conjugate vaccine product is licensed for use in individuals 56 years or older, ACIP recommends using one of the products for HIVinfected individuals in this age group because the only meningococcal vaccine licensed for use in adults 56 or older, meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur), has not been studied in patients with HIV infection.
Meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur) is the only licensed meningococcal vaccine for adults aged [greater than or equal to] 56 years; however, no data are available on use of MPSV4 in HIV-infected adults.
In a separate advisory, the FDA warned against falsified meningitis vaccines Menomune ACY-W135 (10 doses/vial) with batch numbers UH301AA (with expiry dates 29 April 2017 and 28 February 2016) and UH299AA; and diluent for Menomune with batch numbers UH262AA and D0953-1.
meningitidis bacteria that cause meningococcal disease (A, C, W, and Y): They are the meningococcal polysaccharide vaccine (Menomune) and the meningococcal conjugate vaccine (Menactra and Menveo).
Menomune (Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined) is the brand name for Sanofi's tetravalent polysaccharide vaccine sold in the US and Australia to protect against four N.
In 1982, a quadrivalent polysaccharide vaccine (MPSV-4; Menomune, Sanofi Pasteur, Bridgewater, NJ, USA) was introduced; this vaccine targets serogroups A, C, W-135, and Y.
Until now, meningitis vaccines available in the United States were meningococcal polysaccharide vaccine (Menomune) and meningococcal conjugate vaccine (Menactra, Menveo, and MenHibrix), which protect against only four of the five disease serogroups: A, C, Y, and W, according to the Centers for Disease Control and Prevention.
The other two meningococcal vaccines are available in the United States are the polysaccharide vaccine MPSV4 (Menomune, Sanofi-Pasteur) and the conjugate vaccine MCV4 (Menactra, Sanofi-Pasteur).
Two meningococcal vaccines are already available in the United States: the poly saccharide vaccine MPSV4 (Menomune, Sanofi Pasteur) and the conjugate vaccine MCV4 (Menactra, Sanofi Pasteur).
Because of the high risk for meningococcal disease among certain groups and limited data on duration of protection, at its June 2009 meeting ACIP recommended that persons previously vaccinated with either MCV4 or MPSV4 (Menomune, Sanofi Pasteur) who are at prolonged increased risk for meningococcal disease should be revaccinated with MCV4.